SCHEMBL9613113

SCHEMBL9613113

Cc1cc(-c2nnc(C(=O)NCc3ccc(Oc4ccccc4)cc3)o2)cc(Cl)c1O

nearest known ligand 0.59

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 6/20 0.46
HIF1A Q16665 1/20 0.42
MAPK1 P28482 1/20 0.42
ALDH1A1 P00352 3/20 0.42
LMNA P02545 1/20 0.41
CYP3A4 P08684 1/20 0.41
HTT P42858 1/20 0.41
MMP13 P45452 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MAPT P10636 1/20 0.41
MCL1 Q07820 1/20 0.41
HPGD P15428 3/20 0.41
KDM4E B2RXH2 1/20 0.41
LIPG Q9Y5X9 1/20 0.41
AKR1C3 P42330 1/20 0.40
MAPK11 Q15759 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL692489 0.93 MAPK14 (0.45) MAPK14HIF1AALDH1A1LMNACYP3A4
SCHEMBL692923 0.86 FFAR1 (0.45) MAPK14HIF1AMMP13MAPTMAPK11
SCHEMBL31591609 0.84 KMT2A (0.49) MAPK14ALDH1A1LMNACYP3A4HTT
SCHEMBL690828 0.83 SMN1; SMN2 (0.48) ALDH1A1LMNAHTTSMN1; SMN2MAPT
SCHEMBL9611041 0.82 MAPK1 (0.57) MAPK14MAPK1ALDH1A1LMNAHTT
SCHEMBL690195 0.79 AKR1C2 (0.46) MAPK14MAPK1ALDH1A1LMNASMN1; SMN2
SCHEMBL691568 0.79 RAB9A (0.47) MAPK14MAPK1ALDH1A1LMNAHTT
SCHEMBL12285316 0.78 MECP2 (0.47) MAPK14HIF1ALMNACYP3A4HTT
SCHEMBL692348 0.77 MEN1 (0.49) MAPK14MAPK1
SCHEMBL692220 0.77 HIF1A (0.47) HIF1AALDH1A1SMN1; SMN2MAPTLIPG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120136003-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH 2012-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120136003-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES CFTR, PKD1, PKD2 MAPK14 3853/4885HIF1A 1855/4885MAPK1 2718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.